RankAlpha logo
Back to Rankings

BBLG

Bone BiologicsC
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
The constructive case is that BBLG still has a defined clinical-regulatory path for NB1: the Australia pilot is underway, the study design is set at up to 30 subjects, and management frames that work as a bridge toward a later U.S. IDE and PMA path [#10-K-2026-03-02].
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Clinical enrollment slippage or weak data from the Australia NB1 pilot
Momentum
82
Value
57
Sentiment
25
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.90 · Bull $2.20 · Bear $0.35
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $22.20
Why
Momentum82 · Δ7d -
Value57 · Δ7d +0.1
Sentiment25 · Δ7d -
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
82
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
57
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.3
Sentiment
25
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade

Composite grade C. Momentum 81.9 / Value 57.4 / Sentiment 24.5

Fundamentals (TTM)
As of 2026-06-01
Market Cap
$2.3M
Beta
0.75
Shares Out
1.8M
P/E (TTM) · Derived
-0.0
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.32
Rev YoY
-
EPS YoY
+97.4%
Gross Margin
-
Op Margin
-
Net Debt
-$3.33M
Current Ratio
19.00
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology